SCHEMBL6806724

SCHEMBL6806724

Cc1nnc(-c2ccc(-c3ccc(C(=O)O)cc3)cc2)o1

nearest known ligand 0.67

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.67
RAB9A P51151 2/20 0.67
MYC P01106 1/20 0.55
RARA P10276 1/20 0.55
RARB P10826 1/20 0.55
RARG P13631 1/20 0.55
KMT2A Q03164 1/20 0.54
NR1H4 Q96RI1 2/20 0.54
PTPN1 P18031 1/20 0.51
CSNK2A2 P19784 1/20 0.50
CSNK2A1 P68400 1/20 0.50
RXRA P19793 1/20 0.49
RXRB P28702 1/20 0.49
GPR84 Q9NQS5 1/20 0.48
HDAC6 Q9UBN7 1/20 0.47
MAPK14 Q16539 3/20 0.46
GSK3B P49841 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL70030 0.98 NPC1 (0.69) NPC1RAB9AMYCRARARARB
SCHEMBL11438341 0.85 NPC1 (0.89) NPC1RAB9AMYCRARARARB
SCHEMBL24340789 0.84 KDM4E (0.54) NPC1RAB9AGPR84HDAC6MAPK14
SCHEMBL12171910 0.84 RAB9A (0.74) NPC1RAB9AMYCRARARARB
SCHEMBL4856436 0.84 MAPK14 (0.67) NPC1RAB9ARARARARBRARG
SCHEMBL7448719 0.84 MAPK14 (0.57) NPC1RAB9AMYCRARARARB
SCHEMBL5659598 0.84 MAPK14 (0.67) NPC1RAB9ARARARARBRARG
SCHEMBL5122607 0.84 MAPK14 (0.60) NPC1RAB9ARARARARBRARG
SCHEMBL461441 0.83 NPC1 (0.49) NPC1RAB9AMYCGPR84HDAC6
SCHEMBL12171414 0.82 NPC1 (0.96) NPC1RAB9AMYCRARARARB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040063686-A1 Carboxamide compounds and their use as antagonists of a human 11cby receptor JOHNSON CHRISTOPHER NORBERT (GB) 2004-04-01 US disclosed
EP-1305304-A1 CARBOXAMIDE COMPOUNDS AND THEIR USE AS ANTAGONISTS OF A HUMAN 11CBY RECEPTOR SMITHKLINE BEECHAM PLC (GB) 2003-05-02 EP disclosed
EP-0917530-B1 TETRAHYDROISOQUINOLINE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS SMITHKLINE BEECHAM PLC (GB) 2003-02-19 EP disclosed
WO-2002010146-A1 CARBOXAMIDE COMPOUNDS AND THEIR USE AS ANTAGONISTS OF A HUMAN 11CBY RECEPTOR SMITHKLINE BEECHAM P.L.C. (GB) 2002-02-07 WO disclosed
EP-0799226-B1 TETRACYCLIC SPIRO COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THEIR USE AS 5HT1D RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM PLC (GB) 2001-02-07 EP disclosed
US-6046210-A ANTIPSYCHOTIC AGENTS SMITHKLINE BEECHAM P.L.C. (GB) 2000-04-04 US disclosed
US-5972951-A Tetracyclic spiro compounds, process for their preparation and their use as 5HT1D receptor antagonists SMITHKLINE BEECHAM PLC (GB) 1999-10-26 US disclosed
WO-1996019477-A1 TETRACYCLIC SPIRO COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THEIR USE AS 5HT1D RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM PLC (GB) 1996-06-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040063686-A1 Carboxamide compounds and their use as antagonists of a human 11cby receptor CNR1, GPR3, CCKAR NPC1 823/4885RAB9A 1643/4885MYC 2382/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.